Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

NODTHERA LIMITED

Home Clinical Trial Sponsors and OrganizationsNODTHERA LIMITED

NODTHERA LIMITED

SUITE 8, THE MANSION CHESTERFORD, Chesterford, United Kingdom

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

5

0 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

3

60.0%

Phase 2

2

40.0%

Trial Status Distribution

Completed

4

80.0%

Recruiting

1

20.0%

Clinical Trials

Trials sponsored by this organization (5)

Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)

Oct 202582 participants

Evaluate the Efficacy and Safety of NT-0796 in Participants With Obesity With or Without Type 2 Diabetes Mellitus

May 2025176 participants

Effects of NT-0796 in Obese Participants at Risk of Cardiovascular Disease

Oct 202367 participants

A study investigating the safety, absorption, and elimination of NT 0150, a new compound that may potentially be used in the treatment of brain disorders, like Alzheimer’s disease and Parkinson’s disease.

53 participants

Effects of NT-0796 in Healthy Volunteers and Patients with Parkinson’s Disease

14 participants

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials5
Approvals
News

Back to Organizations